Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$2.58 - $4.25 $36,512 - $60,146
14,152 New
14,152 $51,000
Q4 2023

Feb 26, 2024

SELL
$1.19 - $2.42 $16,387 - $33,325
-13,771 Reduced 40.39%
20,322 $47,000
Q3 2023

Nov 14, 2023

BUY
$1.15 - $1.67 $39,206 - $56,935
34,093 New
34,093 $44,000
Q4 2022

Feb 15, 2023

SELL
$0.5 - $1.01 $7,067 - $14,276
-14,135 Reduced 41.72%
19,745 $15,000
Q3 2022

Nov 07, 2022

BUY
$0.82 - $1.73 $27,781 - $58,612
33,880 New
33,880 $29,000
Q1 2022

May 17, 2022

SELL
$1.04 - $1.7 $65,566 - $107,176
-63,045 Closed
0 $0
Q4 2021

Feb 17, 2022

BUY
$1.51 - $2.59 $76,772 - $131,683
50,843 Added 416.68%
63,045 $101,000
Q3 2021

Nov 12, 2021

BUY
$2.2 - $3.17 $26,844 - $38,680
12,202 New
12,202 $30,000
Q1 2021

May 19, 2021

SELL
$2.6 - $4.43 $155,911 - $265,649
-59,966 Closed
0 $0
Q4 2020

Feb 24, 2021

BUY
$1.95 - $3.6 $116,933 - $215,877
59,966 New
59,966 $215,000

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $360M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.